Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies FE, Delforge M, Weisel K, Marshall TS, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D. Rodríguez Otero P, et al. Among authors: mojebi a. Leuk Lymphoma. 2023 Nov-Dec;64(11):1864-1869. doi: 10.1080/10428194.2023.2235042. Epub 2023 Jul 27. Leuk Lymphoma. 2023. PMID: 37497883 No abstract available.
Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis.
Abderhalden LA, Wu P, Amonkar MM, Lang BM, Shah S, Jin F, Frederickson AM, Mojebi A. Abderhalden LA, et al. Among authors: mojebi a. J Gastrointest Cancer. 2023 Dec;54(4):1031-1045. doi: 10.1007/s12029-023-00932-5. Epub 2023 May 23. J Gastrointest Cancer. 2023. PMID: 37219679 Free PMC article. Review.
Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.
Black CM, Keeping S, Mojebi A, Ramakrishnan K, Chirovsky D, Upadhyay N, Maciel D, Ayers D. Black CM, et al. Among authors: mojebi a. Front Oncol. 2022 Apr 28;12:868490. doi: 10.3389/fonc.2022.868490. eCollection 2022. Front Oncol. 2022. PMID: 35574411 Free PMC article.
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Rodriguez-Otero P, Ayers D, Cope S, Davies FE, Delforge M, Mojebi A, Jansen JP, Weisel K, Hege K, Dhanasiri S. Rodriguez-Otero P, et al. Among authors: mojebi a. Leuk Lymphoma. 2021 Oct;62(10):2482-2491. doi: 10.1080/10428194.2021.1913143. Epub 2021 Apr 24. Leuk Lymphoma. 2021. PMID: 33896344
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma.
Keeping S, Xu Y, Chen CI, Cope S, Mojebi A, Kuznik A, Konidaris G, Ayers D, Sasane M, Allen R, Huynh TM, Popoff E, Freeman M, Andria ML, Fury MG, Singh K, Stockfleth E, Challapalli A, Schmults CD. Keeping S, et al. Among authors: mojebi a. Future Oncol. 2021 Feb;17(5):611-627. doi: 10.2217/fon-2020-0823. Epub 2020 Oct 14. Future Oncol. 2021. PMID: 33052055 Free article.